Jason Rusk

530 total citations
9 papers, 419 citations indexed

About

Jason Rusk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Organic Chemistry. According to data from OpenAlex, Jason Rusk has authored 9 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 1 paper in Organic Chemistry. Recurrent topics in Jason Rusk's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (4 papers) and Peptidase Inhibition and Analysis (3 papers). Jason Rusk is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (4 papers) and Peptidase Inhibition and Analysis (3 papers). Jason Rusk collaborates with scholars based in United States, Canada and South Africa. Jason Rusk's co-authors include Gary M. Clark, Marta Hamilton, Julie Wolf, Karsten Witt, Pablo J. Cagnoni, Shannon E. Beard, Maria Roche, Ursula A. Matulonis, Michael V. Seiden and Franco M. Muggia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Jason Rusk

9 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Rusk United States	7	291	241	141	36	26	9	419
Knut Breistøl Norway	11	255 0.9×	193 0.8×	140 1.0×	35 1.0×	10 0.4×	11	499
Vince D. Cataldo United States	8	208 0.7×	210 0.9×	200 1.4×	13 0.4×	19 0.7×	17	520
Kristell Marzin Germany	11	196 0.7×	312 1.3×	169 1.2×	9 0.3×	41 1.6×	18	545
Y. M. Rustum United States	13	270 0.9×	84 0.3×	172 1.2×	39 1.1×	24 0.9×	21	449
Whitney P. Kirschbrown United States	10	214 0.7×	107 0.4×	111 0.8×	38 1.1×	48 1.8×	16	416
Silvia Marchetti Italy	8	242 0.8×	126 0.5×	52 0.4×	12 0.3×	8 0.3×	25	402
Elena Collovà Italy	8	155 0.5×	140 0.6×	45 0.3×	25 0.7×	19 0.7×	23	352
JB Vermorken Netherlands	6	217 0.7×	104 0.4×	103 0.7×	11 0.3×	8 0.3×	11	325
Floris M Wachters Netherlands	10	306 1.1×	309 1.3×	191 1.4×	44 1.2×	9 0.3×	16	522
Ruben A.G. van Eerden Netherlands	11	107 0.4×	76 0.3×	78 0.6×	58 1.6×	38 1.5×	24	319

Countries citing papers authored by Jason Rusk

Since Specialization

Citations

This map shows the geographic impact of Jason Rusk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Rusk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Rusk more than expected).

Fields of papers citing papers by Jason Rusk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Rusk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Rusk. The network helps show where Jason Rusk may publish in the future.

Co-authorship network of co-authors of Jason Rusk

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Rusk. A scholar is included among the top collaborators of Jason Rusk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Rusk. Jason Rusk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Hirsch, Fred R., Fairooz F. Kabbinavar, Tim Eisen, et al.. (2011). A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(26). 3567–3573. 67 indexed citations

Hirsch, Fred R., Rafał Dziadziuszko, Wilbur A. Franklin, et al.. (2009). Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit. Journal of Clinical Oncology. 27(15_suppl). 8026–8026. 9 indexed citations

Weiss, Glen J., et al.. (2007). Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial. Journal of Thoracic Oncology. 2(10). 933–938. 5 indexed citations

Goss, Glenwood, Lillian L. Siu, Isabelle Gauthier, et al.. (2006). A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemotherapy and Pharmacology. 58(5). 703–710. 7 indexed citations

Hamilton, Marta, Julie Wolf, Jason Rusk, et al.. (2006). Effects of Smoking on the Pharmacokinetics of Erlotinib. Clinical Cancer Research. 12(7). 2166–2171. 240 indexed citations

Hamilton, Marta, Julie Wolf, Jianfeng Lü, et al.. (2005). Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib. 65. 1451–1451. 16 indexed citations

Seiden, Michael V., Franco M. Muggia, Ursula A. Matulonis, et al.. (2004). A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecologic Oncology. 93(1). 229–232. 59 indexed citations

Siu, L.L., Geraldine Goss, Jean Powers, et al.. (2003). 544 A phase I trial of the novel nucleoside analog osi-7836 given on days 1 and 8 every 3 weeks: ncic ctg ind. 147. European Journal of Cancer Supplements. 1(5). S165–S165. 3 indexed citations

Mohrbacher, Ann, Stephanie A. Gregory, Don A. Gabriel, Jason Rusk, & Francis J. Giles. (2002). Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. Cancer. 94(10). 2645–2652. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact